Boundless Bio is in a bind. A phase 1/2 trial has revealed the shortcomings of Boundless’ lead candidate, prompting the ...

The adjustment follows a reassessment of the company’s lead CHK1 inhibitor program and its potential in the oncology market. Leerink Partners’ decision is based on the recent shift in ...

The liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies, including immunotherapies and targeted treatments. Increased R&D investment.

Boundless will host a live webcast and conference call on Tuesday, May 27 at 8:00 am ET to discuss these updates. To access the webcast and slides, please visit Events & Presentations in the Investors ...